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Abstract

Rises in cytosolic Ca
2+ concentration ([Ca 2+ ]cyt) are central in platelet activation, yet many aspects of the underlying mechanisms are poorly understood. Most studies examine how experimental manipulations affect agonist-evoked rises in [Ca 2+ ]cyt, but these only monitor the net effect of manipulations on the processes controlling [Ca 2+ ]cyt (Ca 2+ buffering, sequestration, release, entry and removal), and cannot resolve the source of the Ca 2+ or the transporters or channels affected. To investigate the effects of protein kinase C (PKC) on platelet Ca 2+ signalling, we here monitor Ca 2+ flux around the platelet by measuring net Ca 2+ fluxes to or from the extracellular space and the intracellular Ca 2+ stores, which act as the major sources and sinks for Ca 2+ ]cyt and [Na + ]cyt were monitored using Fura-2 and SFBI respectively. PKC inhibition using Ro-31-8220 or bisindolylmaleimide I potentiated ADP-and thrombinevoked rises in [Ca 2+ ]cyt in the absence of extracellular Ca 2+ . PKC inhibition potentiated ADP-evoked but reduced thrombin-evoked intracellular Ca 2+ release and Ca 2+ removal into the extracellular medium. SERCA inhibition using thapsigargin and 2,5-di(tert-butyl) l,4-benzohydroquinone abolished the effect of PKC inhibitors on ADP-evoked changes in [Ca 2+ ]cyt but only reduced the effect on thrombin-evoked responses. Thrombin evokes substantial rises in [Na + ]cyt which would be expected to reduce Ca 2+ removal via the Na + /Ca 2+ exchanger (NCX). Thrombin-evoked rises in [Na + ]cyt were potentiated by PKC inhibition, an effect which was not due to altered changes in non-selective cation permeability of the plasma membrane as assessed by Mn 2+ quench of Fura-2 fluorescence. PKC inhibition was without effect on thrombin-evoked rises in [Ca 2+ ]cyt following SERCA inhibition and either removal of extracellular Na + or inhibition of Na + /K + -ATPase activity by removal of extracellular K + or treatment with digoxin. These data suggest that PKC limits ADP-evoked rises in [Ca 2+ ]cyt by acceleration of SERCA activity, whilst rises in [Ca 2+ ]cyt evoked by the stronger platelet activator thrombin are limited by PKC through acceleration of both SERCA and Na + /K + -ATPase activity, with the latter limiting the effect of thrombin on rises in [Na + ]cyt and so forward mode NCX activity. The use of selective PKC inhibitors indicated that conventional and not novel PKC isoforms are responsible for the inhibition of agonist-evoked Ca 2+ signalling.
Introduction
The importance of rises in cytosolic Ca 2+ concentration ([Ca 2+ ]cyt) for the adhesion and aggregation of human platelets is well established, and this has encouraged significant interest in the molecular mechanisms underlying the creation and control of agonist-evoked rises in [Ca 2+ ]cyt in these cells. Most studies examine how experimental manipulation of channels, transporters or intermediate signalling proteins affect agonist-evoked rises in [Ca 2+ ]cyt in suspensions of Fura-2-or Fluo-4-loaded human platelets. Yet these studies are limited by their ability to only monitor the net effect of any experimental manipulation on each of the component processes involved in controlling [Ca 2+ ]cyt (Ca 2+ buffering, sequestration, release, entry and removal), and lack the ability to resolve the source of the Ca 2+ or the transporters or channels affected. Recent work in human platelets has highlighted the many pitfalls of drawing conclusions as to the molecular pathways involved in eliciting Ca 2+ signals based solely on measurements of [Ca 2+ ]cyt [1] [2] [3] .
A simple method for more accurately tracking the Ca 2+ flux around the platelet is to measure the net Ca 2+ fluxes to or from the extracellular space and the intracellular Ca 2+ stores, which act as the major sources and sinks for Ca 2+ influx into and efflux from the cytosol. We have recently developed and validated methods to measure agonist-evoked changes in extracellular and intracellular store Ca 2+ concentrations ([Ca 2+ ]ext and [Ca 2+ ]st, respectively) in platelet cell suspensions [3, 4] , which can be utilized alongside the measurement of agonist-evoked changes in [ . However these kinases have a large variety of different molecular targets in platelets that could mediate the effect of this kinase on platelet Ca 2+ signalling, with a number of publications suggesting a variety of mechanisms including inhibition of phospholipase C [6, 7] , stimulation of inositol-1,4,5-trisphosphate (IP3) breakdown [8, 9] , stimulation of the plasma membrane Ca 2+ -ATPase (PMCA) [10, 11] , stimulation of sarco/endoplasmic reticulum Ca 2+ -ATPases (SERCAs) [12] and in the case of ADP, desensitization of the receptor [13] . Since inhibition of PMCAs does not abolish the potentiatory effect of PKC inhibitors on thrombin-evoked Ca 2+ rises, PMCAs do not appear to be involved in the response [14] . However, there is currently no consensus as to which of the other above target(s) may be principally responsible for the observed effects of PKC on agonist-evoked Ca 2+ signalling.
ADP activates human platelets via actions on two receptors. The P2Y1 receptor couples via Gq to phospholipase C-β (PLC-β) leading to the formation of IP3, which releases Ca 2+ from the dense tubular system (DTS) [15, 16] . The P2Y12 receptor (formerly known as P2T or P2AC) couples via Gi to adenylyl cyclase [17] and phosphoinositide 3-kinase [18] . Thrombin activates human platelets via the protease-activated receptors (PARs) 1 and 4 [19] . PAR-1 and PAR-4 couple via Gq to PLC-β resulting in Ca 2+ release from the DTS via IP3 formation.
In addition, thrombin releases Ca 2+ from acidic organelles via the formation of nicotinic acid adenine dinucleotide phosphate (NAADP) [4, 20] .
Here we have examined the role of PKC in ADP-and thrombin-evoked Ca 2+ signalling in human platelets utilizing a more comprehensive analysis of Ca 2+ flux around the platelet than hitherto in an attempt to better identify the major molecular targets though which PKC regulates platelet Ca 2+ signalling. We provide evidence that SERCA appears to be a common target of PKC during ADP-and thrombin-evoked Ca 2+ signalling in human platelets and that the Na + /K + -ATPase may act as a secondary PKC target when platelets are stimulated with the stronger platelet activator thrombin.
Materials and Methods
Materials
SBFI/AM and Fura-2/AM were from Texas Fluorescence Laboratories (Austin, TX, USA). PKCθ/δ inhibitor was from Merck Millipore (Nottingham, UK). Fluo-5N/AM and Fluo-4 K + salt were from Invitrogen Ltd (Paisley, UK). Bisindolylmaleimide I (Bisindo I) and BCECF/AM were from Tocris Bioscience (Bristol, UK). Gö6976 was from Abcam (Cambridge, UK). ADP, apyrase, digoxin, Ro-31-8220, thapsigargin, thrombin and 2,5-di(tert-butyl) l,4-benzohydroquinone (TBHQ) were from Sigma-Aldrich (Gillingham, UK). All other reagents were of analytical grade.
Platelet preparation
Blood was collected under written informed consent by venepuncture from healthy drug-free volunteers with local ethical committee approval. The experiments conformed to the guidelines stated in the Declaration of Helsinki. Platelet-rich plasma prepared as previously described [20].
Cytosolic Ca 2+ measurement
PRP was incubated with 2 μM Fura-2/AM for 45 min at 37 °C. Platelets were collected by centrifugation at 350 × g for 20 min and resuspended in HEPES-buffered saline (HBS; 145 mM NaCl, 10 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid), 10 mM D-glucose, 5 mM KCl, 1 mM MgSO4, pH 7.45) supplemented with 0.1% w/v BSA, 200 μM CaCl2 and 40 μg ml -1 apyrase (supplemented HBS). Fluorescence was recorded from 1 ml stirred aliquots of platelet suspension at 37 °C using a Cairn Research Spectrophotometer (Cairn Research, Faversham, UK) with excitation at 340 and 380 nm and emission at 500 nm. Changes in [Ca 2+ ]cyt were monitored using the 340/380 nm fluorescence ratio and calibrated according to the method of Grynkiewicz et al. [21] .
Measurement of Ca
2+ release into the extracellular medium 2.5 µM Fluo-4 K + salt was added to washed platelets suspended in supplemented HBS immediately prior to the start of the experiments. Fluo-4 fluorescence was recorded with excitation at 480 nm and emission at 515 nm, and calibrated as previously described [3] . A validation and quantitative analysis of this technique is presented in [3] . Ro-31-8220 and BisIndo I have fluorescent properties at these wavelengths which could be overcome by performing calibration experiments in the presence and absence of Ro-31-8220 and BisIndo I.
Measurement of intracellular store Ca
2+ concentration ([Ca 2+ ]st)
The use of Fluo-5N-loaded platelets to measure [Ca 2+ ]st has previously been described [4] . PRP was incubated with 250 nM Fluo-5N/AM for 2 h at 37 °C. Cells were then collected by centrifugation at 350 × g for 20 min and resuspended in supplemented HBS to which 100μM RGDS was added. RGDS peptide was included in all experiments to prevent aggregation and therefore artefactual decreases in Fluo-5N fluorescence. RGDS at this concentration has previously been demonstrated not to affect [Ca 2+ ]cyt signals in human platelets [22] . It was not possible to calibrate Fluo-5N measurements made in the presence of PKC inhibitors, as there were differential fluorescence effects of these drugs at the maximal and minimal fluorescences of Fluo-5N. However, it was possible to compensate for this autofluorescence to enable comparison of raw fluorescence values by correcting these values by subtracting the increase in fluorescence observed after addition of PKC inhibitors to the media at the end of Fmin measurements as previously described [4] . 
Cytosolic
Statistical analysis
Values stated are mean ± SEM of the number of observations (n) indicated. Analysis of statistical significance was performed either using a paired Student's t-test, or a repeated measures ANOVA followed by a post hoc Bonferroni multiple comparisons test. P < 0.05 was considered significant. ]cyt signals to 226.9 ± 9.1% or 230.7 ± 46.4% of control respectively ( Fig. 1A, B ; both n = 7; P <0.05). Similarly, the rises in [Ca 2+ ]cyt evoked by thrombin (0.5 units ml -1 ) in the absence of extracellular Ca 2+ were increased by pretreatment for 10 minutes at 37°C with Ro-31-8220 (10 µM; Fig. 1C ; 245.5 ± 6.1% of control; n = 5, P < 0.05) or BisIndo I (5 µM: Fig. 1D ; 206.0 ± 5.8%; n = 6; P < 0.05).
Results
PKC inhibitors potentiate ADP-and thrombin-evoked increases in [Ca
ADP stimulation of platelets elicits Ca 2+ signalling through the activation of the PLC-coupled P2Y1 receptor, and is potentiated by activation of the P2Y12-mediated downregulation of adenylyl cyclase [21, 23] . Experiments were performed to examine whether P2Y12 activity was a prerequisite for PKC-mediated inhibition of ADP-evoked Ca 2+ signals. As shown in Fig. 1E and Fig. 1F , pretreatment of platelets with the P2Y12 inhibitor, MeSAMP (75 μM), reduced ADP-evoked Ca 2+ signals to 79.4 ± 5.0% of control (n = 5; P < 0.05), in agreement with previous findings [24] . Pretreatment of Fura-2-loaded platelets with 50 µM Ro-31-8220 was found to elicit the same potentiatory effect in both the presence (179.9 ± 24.0% of MeSAMP-treated control; n = 5; P < 0.05) and absence of MeSAMP (174.0 ± 16.1% of untreated control; n = 5; P < 0.05). These results demonstrate that the inhibitory effects of PKC on ADP-evoked Ca 2+ signalling are mediated downstream of P2Y1-and not P2Y12-receptor stimulation in human platelets.
Previous work has demonstrated that the inhibitory effects of PKC on thrombin-evoked platelet Ca 2+ signalling are elicited downstream of the activation of PAR1 but not PAR4 [14] . Since ADP can be released from dense granules upon platelet stimulation with thrombin, experiments were also performed to examine whether autocrine ADP stimulation plays a role in thrombin-evoked Ca 2+ release. Pre-treatment of platelets with both MeSAMP (50 µM) and the P2Y1 inhibitor, MRS-2179 (75 µM), elicited no significant inhibition of thrombin-evoked Ca 2+ release ( Fig. 1G ; 92.8 ± 5.8% of control; n = 6; P = 0.27). In contrast, this combination of inhibitors significantly inhibited thrombin-evoked Ca 2+ signals when platelets were stimulated in the presence of external Ca 2+ ( Fig. 1H ; 76.7 ± 7.8% of control; n = 6; P < 0.05), demonstrating that the inhibitors were functional. These results demonstrate that autocrine ADP stimulation was not responsible for PKC-mediated inhibition of thrombin-evoked Ca 2+ signals under the conditions used in this study.
PKC inhibitors potentiate ADP-evoked intracellular Ca 2+ release and Ca 2+ removal into the extracellular medium
We investigated whether the effects of the PKC inhibitors on ADP-or thrombin-evoked rises in [Ca 2+ ]cyt were due to an increase in the net rate of Ca 2+ release from platelet intracellular Ca 2+ stores [6-9, 12, 13] or a reduction in the rate of removal of Ca 2+ into the extracellular medium [10, 11] .
Pretreatment of Fluo-5N-loaded platelets with 10 µM Ro-31-8220 increased the ADP-evoked decrease in [Ca 2+ ]st to 242.1 ± 39.9% of control ( Fig. 2A ; n = 8; P < 0.05). ADP-evoked Ca 2+ removal into the extracellular medium was enhanced after pretreatment with Ro-31-8220 or BisIndo I (209.6 ± 39.9% or 121.6 ± 8.0% of control respectively; Fig. 2B , C; both n = 7; P < 0.05). These data therefore suggest that the potentiation of ADP-evoked Ca 2+ release was mediated via the potentiation of net Ca 2+ release from intracellular stores, whilst the increase in Ca 2+ removal was likely to be an indirect, compensatory response to the greater rise in [Ca 2+ ]cyt.
SERCA inhibition abolishes the effect of PKC inhibitors on ADP-evoked changes in [Ca
2+ ]cyt
Previous work has shown that treatment with phorbol esters, which stimulate PKC, increases Ca 2+ sequestration in permeabilised platelets [25] and increases the Vmax of SERCA [12] . ]st might be due to a reduction in SERCA activity. This was done by examining the effects of concurrent inhibition of PKC and SERCAs (Fig. 3) . Inhibition of SERCAs was achieved by treatment with a combination of both thapsigargin and TBHQ (TGT), to ensure that both the SERCA2b and SERCA3 isoforms present in human platelets were fully inhibited, as SERCA3 has previously been reported to be relatively insensitive to thapsigargin [26, 27] . Addition of SERCA inhibitors at the same time as ADP potentiated ADP-evoked rises in [Ca 2+ ]cyt (529.0 ± 97.2% of control; n = 5; P < 0.05) as expected. In the presence of SERCA inhibitors, Ro-31-8220 had no significant additional effect on ADPevoked rises in [Ca 2+ ]cyt ( Fig. 3A; 108.1 ± 4.6% of SERCA-inhibited control; n = 5; P > 0.1). However, as expected, Ro-31-8220 still potentiated ADP-evoked rises in [Ca 2+ ]cyt in cells from the same preparations not treated with SERCA inhibitors ( Fig. 3B ; 209.1 ± 14.5% of control; n = 5; P < 0.05). These results suggest that PKC upregulates the activity of SERCAs during ADP-evoked Ca 2+ signals, and that loss of this upregulation can account for the potentiation of ADP-evoked rises in [Ca 2+ ]cyt by PKC inhibitors.
PKC inhibitors inhibit thrombin-evoked intracellular Ca 2+ release and Ca 2+ removal into the extracellular medium
In platelets stimulated with the strong activator thrombin, PKC inhibition using BisIndo I reduced the net release of Ca 2+ from the intracellular stores (35.6 ± 21.0% of control; n = 6; P < 0.05; Fig 4A) as well as reducing the thrombin-evoked rise in [Ca 2+ ]ext (22.0 ± 4.3% or 31.8 ± 3.2 % of control for BisIndo I or Ro-81-3220 respectively; Fig. 4B , C; n = 7 or 6; both P < 0.05). These data suggests that the principal effect of PKC on thrombin-evoked Ca 2+ signalling is inhibition of Ca 2+ removal from the cytosol, whilst the reduced emptying of the intracellular stores is likely an indirect response to the greater rise in [Ca 2+ ]cyt (either by affecting the electrochemical gradient for Ca 2+ release and/or providing a greater supply of Ca 2+ to sequestration mechanisms such as SERCA).
PKC inhibitors potentiate thrombin-evoked changes in [Na
+ ]cyt
The data presented above suggested that the principal action of PKC in thrombin-stimulated platelets was to inhibit Ca 2+ removal across the plasma membrane. This Ca 2+ flux is mediated by both the PMCA and NCX in human platelets [28, 29] , with the PMCA providing a high affinity, low capacity system and the NCX a low affinity, high capacity system. Thrombin evokes substantial rises in [Na + ]cyt from around 5 mM to over 27 mM [30] , which would be expected to influence NCX activity. We therefore investigated the effects of PKC inhibitors on thrombin-evoked changes in [Na + ]cyt in SBFI-loaded platelets to examine whether there was reduced Na + flux into the cytosol which might be due to reduced NCX activity. Surprisingly, pretreatment with BisIndo I (Fig. 5A) or Ro-81-3220 (Fig. 5B) ]cyt (222.5 ± 13.2% of control; n = 6, P < 0.05; Fig. 6A ). Replacing extracellular Na + with NMDG reduced but did not abolish the Ro-81-3220-mediated potentiation of the thrombin evoked rise in [Ca 2+ ]cyt (163.9 ± 8.5% of control; n = 6, P < 0.05; Fig. 6B ). Similarly inhibition of SERCA failed to prevent the potentiating effect of Ro-81-3220 on [Ca 2+ ]cyt in thrombin-stimulated platelets (127.0 ± 1.9% of control; n = 6, P < 0.05; Fig. 6C ). However, following SERCA inhibition in combination with removal of extracellular Na + , pretreatment with Ro 81-3220 was without effect on the thrombin evoked rise in [Ca 2+ ]cyt (102.3 ± 2.4% of control, (n = 6, P > 0.05; fig. 6D ).
This result suggests that PKC activity limits thrombin-evoked rises in [Ca 2+ ]cyt by two different actions. Firstly PKC activity increases SERCA activity, promoting the uptake of Ca 2+ into intracellular stores. Secondly, PKC activity reduces the thrombin-evoked rise in [Na + ]cyt, so reducing inhibition of forward mode Na + /Ca + exchange.
PKC inhibitors have no effect on the thrombin-evoked opening of non-selective cation channels.
To examine whether the effect of PKC inhibitors on thrombin-evoked rises in [Na + ]cyt was due to an enhanced permeability of the platelet plasma membrane to cations, we examined whether PKC inhibitors altered the thrombin-evoked increase in divalent cation entry utilizing Mn 2+ quench of Fura-2 fluorescence [31] . Pre-incubating platelets with the PKC inhibitors BisIndo I or Ro 81-3220, had no discernible effect on the thrombin evoked Mn 2+ quench (Fig. 7) , which was 100.2±3.7% of control (n = 6, p > 0.05) after treatment with BisIndo I (5 µM; Fig 7A) and 97.3±2.7% of control (n=6, p > 0.05; Fig 7B) after treatment with Ro 81-3220 (10 µM). These data demonstrate that PKC is not mediating its inhibitory effects on platelet Ca 2+ signalling via inhibition of plasma membrane non-selective cation channels. ]cyt when cells were concurrently treated with SERCA inhibitors.
PKC inhibitors are without effect on thrombin-evoked rises in [Ca
To physiologically inhibit the Na + /K + -ATPase, extracellular K + was replaced with Na + . In these platelet preparations under control conditions (K + -containing medium), pretreatment with Ro 81-3220 potentiated thrombin-evoked rises in [Ca 2+ ]cyt to 183.0 ± 3.7% of control ( Fig. 8A ; n = 9, P < 0.05) and pretreatment with SERCA inhibitors only partially reduced this potentiation to 128.4 ± 4.7% of control ( Fig. 8B ; n = 9, P < 0.05). In the absence of extracellular K + , Ro 81-3220 potentiated thrombin-evoked rises in [Ca 2+ ]cyt to 165.1 ± 5.6% of control ( Fig. 8C ; n = 9, P < 0.05). These results are as would be expected if both SERCA and Na + /K + -ATPase activity were concurrently upregulated by PKC upon thrombin stimulation. In contrast, when platelets were stimulated with thrombin in a K + -free medium and concurrently treated with SERCA inhibitors, there was no additional effect of Ro 81-3220 on thrombin-evoked rises in [Ca 2+ ]cyt (98.3 ± 3.2% of the K + -free and SERCAinhibited control; Fig. 8D ; n = 9; P > 0.5), suggesting that the Na + /K + -ATPase was responsible for mediating the additional effect of PKC on thrombin-stimulated platelets after SERCA inhibition.
To confirm this finding we pharmacologically inhibited the Na + /K + -ATPase, by pretreating platelets with digoxin (100 μM) for 1 h at 37°C. Following prolonged incubation at 37°C, thrombin-evoked responses were smaller and records more noisy than those observed in earlier experiments, probably due to the leak of Fura-2 from the platelets. Under these conditions, Ro 81-3220 again potentiated thrombin-evoked rises in [Ca 2+ ]cyt in untreated cells to 167.0 ± 10.1% of control ( Fig. 9A ; n = 6, P < 0.05). Pretreatment with SERCA inhibitors reduced this potentiation to 119.6 ± 4.9% of SERCA -inhibited control ( Fig. 9B ; n = 6, P < 0.05) and pretreatment with digoxin reduced it to 146.8 ± 8.6% of control ( Fig. 9C ; n = 6, P < 0.05). However treatment with both SERCA inhibitors and digoxin abolished the potentiation of the thrombin-evoked rise in [Ca 2+ ]cyt by Ro 81-3220 ( Fig. 9D ; 105.0 ± 3.2% of SERCA and digoxin-treated control, n = 6, P > 0.5). This result suggests that the influence of PKC on thrombin-evoked rises in [Ca 2+ ]cyt results from combined increased activity of the Na + /K + -ATPase and SERCAs.
Conventional PKC isoforms mediate inhibitory effects on both ADP-and thrombinevoked Ca 2+ signalling
The data presented above using broad-spectrum PKC inhibitors suggest at least two distinct roles for this kinase in regulating platelet Ca 2+ signalling. However, since human platelets possess a number of PKC isoforms [25] , there is a possibility that the PKC-dependent effects on Na + /K + -ATPase and SERCA activities may be mediated by distinct PKC isoforms. Therefore experiments were conducted to examine which isoforms of PKC might be involved in mediating these inhibitory effects on platelet Ca 2+ signalling. Human platelets are known to express both the conventional PKCα and PKCβ isoforms, and the novel PKC isoforms, PKCδ and PKCθ [25] . These subgroups of PKC isoforms can be differentiated by the response to rises in intracellular Ca 2+ concentration, with the classical isoforms being regulated by Ca 2+ and diacylglycerol binding, whilst the novel isoforms require only diacylglycerol to increase their kinase activity [32] . Experiments were therefore performed to examine the effects on agonist-evoked Ca 2+ signalling of compounds able to differentially inhibit the classical isoforms (Gö6976) and novel isoforms (PKCθ/δ inhibitor) expressed in human platelets. Previous work has demonstrated that Gö6976 can also inhibit the tyrosine kinase, Syk, in platelets [33] . However previous work has shown that the tyrosine kinase inhibitor, Genistein which has been shown to inhibit agonist-evoked Syk activation in human platelets [34] , has no effect on thrombin-or ADP-evoked Ca 2+ release [35, 36] . In addition, a recent report using a specific Syk inhibitor, PRT-060318, found no effect on TRAP-induced Ca 2+ signals at concentrations found to inhibit over 90% of the convulxin-induced Ca 2+ response [37] . These results therefore suggest that any effect of Gö6976 observed on platelet Ca 2+ signalling is limited to its effect on conventional PKC isoforms.
Firstly, we examined the effect of the conventional PKC inhibitor, Gö6976, on thrombin-and ADP-evoked Ca 2+ release. As shown in Figures 10A and 10C , pretreatment with Gö6976 (3 μM) potentiated both ADP-(167.5 ± 22.5 % of control; n = 5, P < 0.05) and thrombinevoked (174.3 ± 9.8% of control; n = 6, P < 0.05) Ca 2+ signals. Similar to our above findings with broad-spectrum PKC inhibitors, the effect of Gö6976 on ADP-evoked Ca 2+ signalling was abolished by the addition of SERCA inhibitors concomitantly with ADP stimulation (101.3 ± 4.2 % of control; Fig.10B ; n = 5, P > 0.05). In contrast, the effect of Gö6976 on thrombin-evoked Ca 2+ signalling was found to only be partially reduced by either inhibition of SERCAs (126.4 ± 3.0 % of control; Fig. 10D ; n = 6, P < 0.05), or replacement of extracellular Na + with NMDG (153.6 ± 6.3 % of control; Fig. 10E ; n = 6, P < 0.05). However, the combination of both of these treatments was found to abolish the effect of Gö6976 on thrombin-evoked Ca 2+ signalling (102. ± 22.5 % of control; Fig. 10F ; n = 6, P > 0.05). These findings are in line with our above results using broad-spectrum PKC inhibitors, and suggest that conventional PKC isoforms are responsible for the inhibitory effects on both SERCAs and the Na + /K + -ATPase.
PKCθ/δ inhibitor potently inhibits novel PKC isoforms with an IC50 of 70 nM for PKCθ, and 350 nM for PKCδ, with no notable effect on conventional PKC isoforms (IC50 > 50 μM for PKCβ) [38] . Pretreatment of Fura-2-loaded human platelets with PKCθ/δ inhibitor was found not to potentiate ADP-evoked Ca 2+ release at lower concentrations (100 or 300 nM; 102.9 ± 5.2 % or 91.4 ± 8.5 % of control; Fig 11A both n = 6 and P > 0.05) and to inhibit ADPevoked Ca 2+ release at higher concentration (1 or 3 μM; 75.4 ± 8.8% or 53.9 ± 14.5% of control; both n = 6 and P < 0.05), suggesting that novel PKC isoforms are not responsible for activating SERCA and Na + /K + -ATPase activity in ADP-stimulated platelets. Further experiments considered the possibility that the activities of novel and conventional PKC isoforms are redundant in modulating ADP-and thrombin-evoked Ca 2+ release. Pretreatment of platelets with Gö6976 alone induced a significant potentiation of both ADP-(146.7 ± 11.3 % of control; n = 6; Fig 11B; P < 0.05) and thrombin-evoked Ca 2+ signals (168.7 ± 13.3 % of control; n = 5; Fig 11C; P < 0.05). In contrast, pretreatment of platelets with PKCθ/δ inhibitor (300 nM) had no significant effect on the Ca 2+ signals elicited by either agonist (92.2 ± 5.5% or 98.5 ± 5.3 % of control for ADP and thrombin respectively; both n = 6 and 5; P > 0.05). When used in combination the effect of these two inhibitors was found to lead to a small but consistent reduction in the potentiation elicited by Gö6976 alone (122.5 ± 7.7% or 151.2 ± 10.9 % of control for ADP and thrombin respectively; n = 6 and 5 respectively). These results therefore support our finding that conventional, but not novel, isoforms of PKC are involved in mediating the inhibitory effect of PKC on platelet Ca 2+ signalling.
Discussion
In this study, we have adopted a more rigorous approach for examining Ca 2+ signalling in platelets than simply monitoring [Ca 2+ ]cyt. By monitoring the flux of Ca 2+ to and from the Ca 2+ sources and sinks which supply the cytosol, in addition to monitoring the [Ca 2+ ]cyt itself, we have been able to show that while PKC has a negative effect on Ca 2+ signalling in ADPand thrombin-stimulated platelets, the principal point of action on this signalling system is distinct for these agonists. Whilst the main effect of PKC on Ca 2+ fluxes during ADP-evoked signalling appeared to be a reduction in net Ca 2+ efflux from intracellular stores, the major mode of action of PKC in thrombin-stimulated platelets appeared to be in facilitating Ca 2+ removal across the plasma membrane. These results highlight the need to look beyond merely examining the net effect of any experimental manipulation of the platelet signalling system on agonist-evoked rises in [Ca 2+ ]cyt, to examine how these manipulations affect the flux of Ca 2+ from or into the component Ca 2+ sources and sinks. By doing this we have demonstrated an agonist-dependent signalling function of the PKC system in human platelets and have been better able to design further experiments to pinpoint the molecular pathways affected. This has allowed us to demonstrate that PKC upregulates SERCA activity in response to both ADP and thrombin, but that Na + /K + -ATPase activity is also affected when the stronger platelet activator thrombin is used (Fig. 12) . The reasons for this difference are currently unclear but may relate to the lower diacylglycerol concentrations observed in platelets stimulated with ADP compared with thrombin [39, 40] . The reduced translocation of PKC to the plasma membrane might limit the ability of PKC to significantly alter the activity of Na + /K + -ATPase in ADP-stimulated platelets [41, 42] . Future work examining the role of modulating diacylglycerol levels in ADP-stimulated platelets might help delineate this pathway further [39] .
By studying the effects of PKC inhibitors that are able to selectively inhibit either the novel or conventional PKC isoforms expressed in human platelets, we have provided evidence that the negative regulation of ADP-and thrombin-evoked Ca 2+ signalling is likely to be selectively mediated via conventional PKC isoforms. This is in line with previous data that demonstrated a role for PKCβ (but not PKCθ or PKCδ) in inhibiting ADP-evoked Ca 2+ signals in human platelets [43] . In contrast, treating platelets with an inhibitor of novel PKC isoforms appears to suppress the Ca 2+ signals elicited by ADP and thrombin. Interestingly, previous work has demonstrated that collagen-evoked Ca 2+ signalling in human platelets is negatively regulated by novel PKC isoforms and positively regulated by conventional PKC isoforms [44] . An agonist-specific effect of isoform-selective PKC inhibition has also been reported for platelet dense granule secretion [45] . These results beg the question as to whether novel PKC isoforms are potentiating collagen-evoked signalling by triggering the same effects on SERCA and Na + /K + -ATPase activity elicited by the conventional isoforms upon thrombin-or ADP-stimulation, or whether there are distinct molecular targets for PKC that modulate collagen-evoked Ca 2+ signals.
Whilst this approach to the study of Ca 2+ signalling does provide a better foundation from which to explore molecular pathways, there are limitations in that it will only identify the net effect of the experimental manipulations on Ca 2+ flux to or from intracellular stores and the extracellular space. This means that counteracting effects on these fluxes may not show up if they cancel themselves out. Thus it is important to note that this analysis only detects the principal effects on the Ca 2+ signalling system, and we cannot rule out additional effects of PKC on the system. In addition, whilst we have been able to identify SERCAs and the Na + /K + -ATPase as the final targets of PKC in this system, we have no ability to distinguish between the possibility that PKC directly regulates the activity of these transporters through phosphorylation, or indirectly through an intermediate signalling protein or binding partner. Thus at this stage we can only speculate on how the Na + /K + -ATPase and SERCAs are regulated by PKC.
Previous work has demonstrated that treatment with PKC-activating phorbol esters increases SERCA activity in permeabilised platelets [12] . Although SERCA activity has been reported to be increased by PKC activation in others cells [46] , we believe our results provide the first evidence for the regulation of SERCA by PKC in intact platelets under the control of physiological agonists. It is possible that this regulation may be direct as phosphoproteomic profiling of platelets has previously shown a serine phosphorylation of SERCA2 [47] . However, Tao and colleagues [12] have previously suggested that PKC may affect SERCA indirectly via phosphorylation of Rap1b. Given that PKC has been shown to phosphorylate and activate Rap1b [48, 49] and that phosphorylation of Rap1b by other kinases is thought to regulate SERCA activity in platelets [50] [51] [52] , Rap1b may be involved in the regulation of SERCA activity by PKC. Further studies investigating the phosphorylation of SERCA and association of Rap1b with SERCA may help distinguish between these possibilities.
The molecular mechanism by which PKC influences Na + /K + -ATPase activity in platelets is less clear. PKC has been reported to increase Na + /K + -ATPase activity in other cell types including arterial smooth muscle [53] and cardiac myocytes [54] . However, unlike with SERCA, there is no evidence for phosphorylation of this protein in the resting platelet phosphoproteome [47] , although given the need for activation with a strong platelet activator for the Na + /K + -ATPase to be influenced by PKC, phosphorylation of this protein might not be expected under resting conditions. In cardiac muscle and several other cell types, Na + /K + -ATPase activity is modulated by association with members of the FXYD family of proteins [55] . However, no members of the FXYD family have been detected in the platelet proteome [56] . Another possibility is that there is a change in surface expression of the Na + /K + -ATPase in thrombin-stimulated platelets. Surface expression of this transporter has been reported to increase more than ten-fold in ADP stimulated platelets as assessed by [ 3 H]-ouabain binding [57] . Given the central role of PKC in granule secretion in platelets [32] , it is not inconceivable that thrombin-evoked activation of PKC may also increase the apparent activity of Na + /K + -ATPase through modulation of its expression in the platelet plasma membrane. ]cyt following SERCA inhibition and removal of extracellular Na + . Fura-2-loaded human platelets were suspended in supplemented HBS (A, C) or a similar medium in which Na + was replaced with NMDG (B, D) containing 200 µM CaCl2 and preincubated with 10 µM Ro-31-8220 or its vehicle, DMSO, for 10 min at 37°C. Extracellular Ca 2+ was then chelated by addition of 1 mM EGTA and the platelets stimulated with 0.5 units ml -1 thrombin and either both 1 µM thapsigargin and 20 µM TBHQ (TGT), or an equal volume of their vehicle, DMSO. Fig. 7 . PKC inhibitors have no effect on the thrombin-evoked opening of non-selective cation channels. Fura-2-loaded human platelets were suspended in a Ca 2+ -free medium, and preincubated with either 5 µM BisIndo I (A), 10 µM Ro-31-8220 (B) or their vehicle, DMSO (A,B), for 10 min at 37°C. 500 μM EGTA was then added followed by the addition of 1 mM MnCl2. Platelets were then stimulated with 0.5 units ml -1 thrombin. An unstimulated control sample is also shown in both panels PKC inhibitors have no effect on the thrombin-evoked opening of non-selective cation channels. Fura-2-loaded human platelets were suspended in a Ca 2+ -free medium, and preincubated with either 5 µM BisIndo I (A), 10 µM Ro-31-8220 (B) or their vehicle, DMSO (A,B), for 10 min at 37°C. 500 μM EGTA was then added followed by the addition of 1 mM MnCl2. Platelets were then stimulated with 0.5 units ml -1 thrombin. An unstimulated control sample is also shown in both panels ]cyt. (A) Fura-2-loaded human platelets were suspended in supplemented HBS containing 200 µM CaCl2, and preincubated with 100 nM, 300 nM, 1 µM or 3 µM PKCθ/δ inhibitor or its vehicle, DMSO, for 10 min at 37°C. Extracellular Ca 2+ was then chelated by addition of 1 mM EGTA before the platelets were stimulated with 50 µM ADP. (B, C) Fura-2-loaded human platelets were suspended in supplemented HBS containing 200 µM CaCl2, and preincubated with 300 nM PKCθ/δ inhibitor, 3 µM Gö6976, both inhibitors or their vehicle, DMSO, for 10 min at 37°C. Extracellular Ca 2+ was then chelated by addition of 1 mM EGTA before the platelets were stimulated with 50 µM ADP (B) or 0.5 units ml -1 thrombin. Results are expressed as mean of percentage control responses. * = P < 0.05 v. control, † = P < 0.05. removal into the extracellular fluid and Ca 2+ sequestration into intracellular stores in an agonist-dependent manner. Upon ADP activation, PKC negatively regulates the Ca 2+ signal by increasing Ca 2+ sequestration back into the dense tubular system through activation of SERCA. Upon thrombin stimulation, PKC additionally regulates Ca 2+ removal from the cytosol into the extracellular space by increasing the activity of the Na + /K + -ATPase. This in turn limits agonist-evoked rises in [Na + ]cyt, which slows Ca 2+ efflux via forward mode Na + /Ca 2+ exchange.
Figure legends
